

Title (en)  
THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA

Title (de)  
THERAPIE FÜR SUBARACHNOIDE BLUTUNG UND ISCHÄMIE

Title (fr)  
TRAITEMENT DE L'HÉMORRAGIE SUBARACHNOÏDE ET DE L'ISCHÉMIE

Publication  
**EP 2800575 B1 20190522 (EN)**

Application  
**EP 12857611 A 20121213**

Priority

- US 201161570264 P 20111213
- CA 2762338 A 20111215
- US 201261617001 P 20120328
- IB 2012057259 W 20121213

Abstract (en)  
[origin: WO2013088382A1] The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefitting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.

IPC 8 full level  
**A61K 38/08** (2019.01); **A61K 38/17** (2006.01); **A61K 38/49** (2006.01); **A61M 31/00** (2006.01); **A61P 9/10** (2006.01); **A61P 25/00** (2006.01)

CPC (source: EP IL KR US)  
**A61K 38/08** (2013.01 - EP IL KR US); **A61P 7/04** (2017.12 - EP IL KR); **A61P 9/00** (2017.12 - EP IL); **A61P 9/10** (2017.12 - EP IL KR); **A61P 25/00** (2017.12 - EP IL); **A61P 25/28** (2017.12 - EP IL); **A61P 29/00** (2017.12 - EP IL); **A61P 43/00** (2017.12 - EP IL); **C07K 5/1008** (2013.01 - IL KR); **C07K 5/1013** (2013.01 - IL KR); **C07K 5/1021** (2013.01 - IL KR); **C07K 5/1024** (2013.01 - IL KR); **C07K 5/1008** (2013.01 - EP); **C07K 5/1013** (2013.01 - EP); **C07K 5/1021** (2013.01 - EP); **C07K 5/1024** (2013.01 - EP)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2013088382 A1 20130620**; AU 2012354072 A1 20140703; AU 2012354072 B2 20170427; CN 104053448 A 20140917; CN 104053448 B 20170405; DK 2800575 T3 20190701; EP 2800575 A1 20141112; EP 2800575 A4 20150923; EP 2800575 B1 20190522; ES 2731266 T3 20191114; IL 233103 A0 20140731; IL 233103 B 20210325; JP 2015501834 A 20150119; JP 2018052962 A 20180405; JP 2020128419 A 20200827; JP 6279483 B2 20180214; JP 6741642 B2 20200819; KR 102114490 B1 20200525; KR 20140108266 A 20140905; KR 20200057802 A 20200526; MX 2014007031 A 20150220; MX 364562 B 20190430; SG 10201604676W A 20160728; SG 11201403239U A 20140926; ZA 201404636 B 20151028

DOCDB simple family (application)  
**IB 2012057259 W 20121213**; AU 2012354072 A 20121213; CN 201280061924 A 20121213; DK 12857611 T 20121213; EP 12857611 A 20121213; ES 12857611 T 20121213; IL 23310314 A 20140612; JP 2014546717 A 20121213; JP 2017217549 A 20171110; JP 2020085748 A 20200515; KR 20147019192 A 20121213; KR 20207014227 A 20121213; MX 2014007031 A 20121213; SG 10201604676W A 20121213; SG 11201403239U A 20121213; ZA 201404636 A 20140624